HOUSTON (Dow Jones) âe” The first federal trial on the risks of Merck & Co.âe(TM)s (MRK) Vioxx edged toward jury deliberations Thursday morning, with closing arguments from the two sides.

Plaintiff attorneys and Merck counsel offered radically opposing characterizations of the pharmaceutical giantâe(TM)s conduct regarding Vioxx, a painkiller that was removed from the market in September 2004 because of concerns that it causes heart attacks. Judge Eldon Fallon will deliver jury instructions at 1:30 p.m. Central time after a lunch break.

The case concerns Richard âeoeDickyâe Irvin, 53 years old, who died in 2001 after taking Vioxx for back pain for a month. The case hinges on whether the nine-member jury accepts the plaintiffâe(TM)s arguments that Merckâe(TM)s shepherding of Vioxx was negligent, and that Vioxx contributed to Irvinâe(TM)s death.

Plaintiff counsel Andy Birchfield emphasized the testimony of a renowned cardiologist, Eric Topol, who said Vioxx can cause heart attacks after as little as four weeks and suggested that Merck tried to intimidate him into not publishing research critical of Merck. Birchfield also pointed out written comments by the Food and Drug Administration criticizing Merck for misleading the public in downplaying the risks of Vioxx.

âeoeYou can make a difference where the FDA couldnâe(TM)t stand up to Merck,âe Birchfiled told the jury. âeoeYour decision will have far-reaching consequences on how drug companies conduct their business.âe

To side with Irvin, the jury must conclude that Vioxx was âeoea cause, not the causeâe(TM) of death, Birchfield said.

Merck counsel Phillip Beck defended Merck as a âeoescience-driven companyâe that has been forthcoming and proactive in researching its medicines and publicizing those results, The drug giant has argued that its decision with Vioxx reflected a multitude of research and that a preponderance found the medicine to be safe.

Beck depicted Topol as self-important and âeoethe kind of guy who doesnâe(TM)t like to be contradicted and has an ax to grind.âe(TM)

Merck argues that there is no evidence that Vioxx can cause heart trouble after such a short period of use, and reiterated expert testimony that Irvinâe(TM)s death was cause by a ruptured artery and that he had heart disease. âeoeVioxx did not cuase Mr. Irvinâe(TM)s death,âe Beck said.

The Houston case comes on the heels of two state cases, the first which issued a $253.4 million verdict against Merck, the second of which sided with the drug company.

We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Merck to pay $830 million to settle investors’ Vioxx...

Merck announced Friday it will pay $830 million to settle investor complaints accusing it of committing...

Merck to pay nearly $1 billion for illegal marketing...

American pharmaceutical company Merck, Sharp & Dohme has agreed to pay $950 million to resolve criminal...

Merck paying more than 3,100 vioxx death claims

Merck & Co. is paying claims by the families of more than 3,100 users of its Vioxx painkiller who...

Settlement limits insurers' claims in Vioxx deal

TRENTON, N.J. (AP) -- Former Vioxx users getting part of a $4.85 billion settlement ending most personal...

Persistence pays in Vioxx litigation

Plaintiffs get close to $5B, but Merck could have done a lot worse. Attorneys who spent nearly one year...

Vioxx settlement payments to begin in August

Merck & Co., manufacturer of Vioxx, announced it will make the first payment of $500 million on Aug....

Grateful and appreciative

You will never know how grateful and appreciative I am for all your efforts and achievements on my behalf. Your whole team is being remembered in my nightly prayers for your continued success in all your endeavors.